KRAS and familial pancreatic carcinoma: Besides the mechanistic importance of these results, this new information reinforces the role of EHMT2 as a potential therapeutic or chemopreventive target for pancreatic cancer and highlights the possibilities of this therapeutic strategy in combination with current inhibitors of the EGFR-KRAS pathway, which are widely available for clinical trials.